XML 40 R5.htm IDEA: XBRL DOCUMENT v2.4.0.8
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) (USD $)
 9 Months Ended
Feb. 28, 2014
Feb. 28, 2013
Cash flows from operating activities:    
Net (loss) income $ (384,532) $ 492,937
Adjustments to reconcile net (loss) income to net cash (used in)provided by operating activities:    
Depreciation and amortization 148,624 164,411
Stock option expense 11,003 17,155
Change in provision for losses on accounts receivable 4,675 (4,133)
Inventory reserve (6,713) 3,891
Decrease in deferred rent liability (10,109) (3,420)
Changes in assets and liabilities:    
Accounts receivable (304,783) 691,339
Inventories (360,407) 111,943
Prepaid expenses and other assets 55,671 (13,548)
Accounts payable and other accrued expenses 81,323 7,362
Other Assets    (2,767)
Accrued compensation (87,654) 30,870
Net cash (used in) provided by operating activities (852,902) 1,496,040
Cash flows from investing activities:    
Purchases of property and equipment (117,365) (249,410)
Net cash used in investing activities (117,365) (249,410)
Cash flows from financing activities:    
Proceeds from sale of common stock 150,000   
Proceeds from exercise of stock options 17,275 40,414
Payments on line of credit or equipment loan    (43,000)
Net cash provided by (used in) financing activities 167,275 (2,586)
Effect of exchange rate changes in cash (1,114) (2,709)
Net (decrease) increase in cash and cash equivalents (804,106) 1,241,335
Cash and cash equivalents at beginning of period 2,469,796 1,077,342
Cash and cash equivalents at end of period 1,665,690 2,318,677
Supplemental Disclosure of Cash-Flow Information:    
Interest 80 302
Income taxes 9,535 108,160
Non-Cash Investing Activities:    
Payment of international regulatory approval fees in exchange for $100,000 due on agreement to purchase Biomerica restricted stock $ 100,000